Andros Pharmaceuticals Co.,Ltd (6917.TWO)
- Previous Close
16.70 - Open
16.70 - Bid 16.15 x --
- Ask 16.50 x --
- Day's Range
16.50 - 16.85 - 52 Week Range
14.30 - 22.05 - Volume
43,000 - Avg. Volume
108,112 - Market Cap (intraday)
738.738M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-1.75 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Andros Pharmaceuticals Co.,Ltd, a biopharmaceutical company, engages in developing novel drug delivery platform technologies. The company develops APC101, a fast-drying, film-forming, and meter-dosed spray, which is in Phase IIa clinical trial to treat pain associated with post-herpetic neuralgia; APC201, a novel dosage form of topical anesthetic that is in Phase I/II clinical trial for treatment of Osteoarthritis; and siRNA, an anti-sense oligonucleotide and DNA candidate. Its preclinical phase products are APC310 and APC501 for anesthesia to intravenous catheter placement and venipuncture; and APC401, a special emulsified solution for anesthesia of post-surgery pain. The company offers LALP cream for dermal analgesic applications; iMinos solution for Alopecia Androgenetica; and T4 endonuclease V. Andros Pharmaceuticals Co.,Ltd was founded in 2008 and is based in Zhubei, Taiwan.
www.andros.com.twRecent News: 6917.TWO
View MorePerformance Overview: 6917.TWO
Trailing total returns as of 4/22/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 6917.TWO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 6917.TWO
View MoreValuation Measures
Market Cap
747.69M
Enterprise Value
416.70M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.68k
Price/Book (mrq)
1.90
Enterprise Value/Revenue
2.05k
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
--
Diluted EPS (ttm)
-1.75
Balance Sheet and Cash Flow
Total Cash (mrq)
--
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--